TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Laekna, Inc. ( (HK:2105) ).
Laekna, Inc. announced the presentation of clinical and preclinical study results for its products LAE102, LAE103, and LAE123 at the 85th scientific sessions of the American Diabetes Association. The studies highlighted the safety and potential efficacy of LAE102 in treating obesity, showing a favorable safety profile and prolonged pathway blocking in healthy volunteers. These findings support further clinical development, potentially enhancing Laekna’s position in the biotechnology industry by advancing treatments for obesity and muscle growth.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$26.46 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a biotechnology company focused on developing innovative therapeutics, particularly in the areas of obesity and muscle growth. The company specializes in creating monoclonal antibodies and other biologics aimed at addressing significant health challenges.
Average Trading Volume: 4,254,951
Technical Sentiment Signal: Buy
See more insights into 2105 stock on TipRanks’ Stock Analysis page.